COHANCE LIFESCIENCES LTD
NSE: COHANCEMarket Closed • NSE
Day range
52 week range
COHANCE LIFESCIENCES LTD closed at INR464.05 (+0.89%) on volume 0.62x its 20-day average, trading 49.44% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -662.5% QoQ
2024-08-06
AGM Announced
Annual General Meeting
2023-12-12
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.10x
High Cash Flow Conversion: CFO/PAT averaged 1.73x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 170.0x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Annual General Meeting | Annual General Meeting | — | 06 Aug 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 12 Dec 2023 |
| 12 Sept 2022 | Dividend | ₹5.00 / share | — | 09 Sept 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 11 Aug 2022 |
| 17 May 2022 | Dividend | ₹1.00 / share | — | 13 May 2022 |
| 16 Feb 2022 | Dividend | ₹2.00 / share | — | 15 Feb 2022 |
| 17 Aug 2021 | Dividend | ₹1.00 / share | — | 13 Aug 2021 |
| 18 Feb 2021 | Dividend | ₹1.00 / share | — | 17 Feb 2021 |
| 28 Sept 2020 | Bonus issue | 1:1 bonus ratio | — | 25 Sept 2020 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules.[1][2]
IndiaHealthcare
Is COHANCE LIFESCIENCES LTD Shariah compliant?
COHANCE LIFESCIENCES LTD is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (2.26%) complies with AAOIFI threshold (≤ 33%).
What is COHANCE LIFESCIENCES LTD's current valuation relative to peers?
COHANCE LIFESCIENCES LTD trades at a P/E of 170.0x compared to the sector median of 37x, and a Price-to-Book of 4.5x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.10x. Interest coverage is 6.4x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 17% while net profit growth averaged -9.8%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.